AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead
AIM ImmunoTech said its Phase 2 pancreatic cancer trial of Ampligen (rintatolimod) plus AstraZeneca’s Imfinzi (durvalumab) after FOLFIRINOX reached final patient enrollment ahead of schedule. The company expects to complete dosing and assess the primary Clinical Benefit Rate endpoint in December 2026, while continuing Phase 3 planning and expanding regulatory and IP efforts.
How this was made
The 30-second read
Why it matters
Final patient enrollment ahead of schedule reduces timeline risk and sets up a defined primary endpoint evaluation window (CBR in December 2026). It also supports continued Phase 3 planning and regulatory/IP expansion, which can improve perceived development readiness.
Market read
The disclosed enrollment milestone is a concrete development step that can shift probability-weighted expectations and trading positioning ahead of the next major readout window.
What to watch
The article does not provide the magnitude of DURIPANC results or any updated Phase 2 efficacy numbers, so traders may be reacting more to timing than to clinical effect size.
Background
AIM ImmunoTech is developing Ampligen (rintatolimod) in metastatic pancreatic cancer, combining it with AstraZeneca’s Imfinzi after FOLFIRINOX, and is planning a Phase 3 program supported by prior named-patient and ongoing study data.
Ticker impact
AIM ImmunoTech said its Ampligen Phase 2 pancreatic cancer trial hit final enrollment ahead of schedule, enabling December 2026 CBR endpoint evaluation.
Likely continued upside bias while traders price forward the December 2026 Clinical Benefit Rate evaluation and Phase 3 readiness, though volatility remains high after a large gap-up.
The article discloses a concrete trial milestone (final enrollment) and ties it to a specific future decision point (CBR evaluation in Dec 2026) plus ongoing Phase 3 planning, which can re-rate probability-weighted outcomes.
Market effects
Reinforces risk-on sentiment for oncology biotech trial progress stories, particularly in pancreatic cancer immunotherapy combinations.
No specific regional market impact beyond global regulatory and IP expansion mentioned by the company.
Uses a Dutch Named Patient Program and ongoing DURIPANC study, supporting the narrative of cross-border clinical development momentum.
Counterpoint
A completed enrollment milestone does not guarantee efficacy; the market may be over-discounting the probability of a favorable CBR outcome before data are available.
Key entities
- companyAIM ImmunoTech
Subject of the article; announced final enrollment completion in its Ampligen Phase 2 pancreatic cancer trial and linked it to a December 2026 CBR evaluation.
- product_candidateAmpligen (rintatolimod)
Therapy whose Phase 2 enrollment milestone enables evaluation of the Clinical Benefit Rate endpoint.
- partner_therapyImfinzi (durvalumab)
AstraZeneca’s drug used in the combination regimen described for the Phase 2 study.
- clinical_studyDURIPANC study
Ongoing study cited as providing encouraging results supporting Phase 3 planning.
